Two Stage Designs for Phase III Trials
Follmann, D.; Proschan, M.
Show abstract
Phase III platform trials are increasingly used to evaluate a sequence of treatments for a specific disease. Traditional approaches to structure such trials tend to focus on the sequential questions rather than the performance of the entire enterprise. We consider two-stage trials where an early evaluation is used to determine whether to continue with an individual study. To evaluate performance, we use the ratio of expected wins (RW), that is, the expected number of reported efficacious treatments using a two-stage approach compared to that using standard phase III trials. We approximate the test statistics during the course of a single trial using Brownian Motion and determine the optimal stage 1 time and type I error rate to maximize RW for fixed power. At times, a surrogate or intermediate endpoint may provide a quicker read on potential efficacy than use of the primary endpoint at stage 1. We generalize our approach to the surrogate endpoint setting and show improved performance, provided a good quality and powerful surrogate is available. We apply our methods to the design of a platform trial to evaluate treatments for COVID-19 disease.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Estimating Counterfactual Placebo HIV Incidence in HIV Prevention Trials Without Placebo Arms Based on Markers of HIV Exposure 93%
- Using simulated infectious disease outbreaks to guide the design of individually randomized vaccine trials 92%
- Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: a scoping review 91%
Similar papers in this journal
- Incorporating data from multiple endpoints in the analysis of clinical trials: example from RSV vaccines 94%
- Incorporating efficacy data from initial trials into subsequent evaluations of vaccines against respiratory syncytial virus 93%
- Causal Estimands for Infectious Disease Count Outcomes to Investigate the Public Health Impact of Interventions 92%
Similar papers in this journal
- Using the Bayesian credible subgroups method to identify populations benefiting from treatment: An application to the Look AHEAD trial 93%
- Using numerical modelling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample 92%
- A scaling approach to estimate the COVID-19 infection fatality ratio from incomplete data 92%
Similar papers in this journal
- Graphing and reporting heterogeneous treatment effects through reference classes 94%
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial 93%
- Machine learning for randomised controlled trials: identifying treatment effect heterogeneity with strict control of type I error 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.